| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 43 | 2025 | 712 | 6.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 27 | 2025 | 186 | 5.880 |
Why?
|
| Neoplasms | 41 | 2021 | 1378 | 5.250 |
Why?
|
| Antineoplastic Agents | 34 | 2026 | 645 | 5.120 |
Why?
|
| Biomarkers, Tumor | 19 | 2025 | 527 | 3.230 |
Why?
|
| Small Cell Lung Carcinoma | 8 | 2019 | 18 | 2.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 466 | 2.550 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2026 | 198 | 2.500 |
Why?
|
| Hedgehog Proteins | 8 | 2013 | 116 | 1.910 |
Why?
|
| MicroRNAs | 10 | 2012 | 714 | 1.910 |
Why?
|
| Adenocarcinoma | 9 | 2017 | 367 | 1.420 |
Why?
|
| Mutation | 16 | 2026 | 2675 | 1.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2021 | 256 | 1.250 |
Why?
|
| Gene Expression Profiling | 9 | 2015 | 799 | 1.210 |
Why?
|
| ErbB Receptors | 6 | 2026 | 128 | 1.200 |
Why?
|
| Maximum Tolerated Dose | 19 | 2021 | 40 | 1.180 |
Why?
|
| Pancreatic Neoplasms | 5 | 2017 | 354 | 1.160 |
Why?
|
| Humans | 122 | 2026 | 65845 | 1.150 |
Why?
|
| Signal Transduction | 16 | 2026 | 3170 | 1.110 |
Why?
|
| Skin Neoplasms | 9 | 2022 | 411 | 1.110 |
Why?
|
| Glutamates | 5 | 2014 | 13 | 1.100 |
Why?
|
| Guanine | 5 | 2014 | 26 | 1.090 |
Why?
|
| Aged | 56 | 2025 | 15147 | 1.080 |
Why?
|
| Molecular Targeted Therapy | 6 | 2020 | 129 | 1.080 |
Why?
|
| Deoxycytidine | 3 | 2017 | 45 | 1.030 |
Why?
|
| Male | 76 | 2025 | 31410 | 1.030 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2014 | 42 | 1.020 |
Why?
|
| Middle Aged | 57 | 2025 | 18501 | 1.000 |
Why?
|
| Adult | 57 | 2020 | 17579 | 0.980 |
Why?
|
| Neoplasm Staging | 18 | 2019 | 554 | 0.960 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2026 | 218 | 0.950 |
Why?
|
| Female | 73 | 2025 | 34425 | 0.940 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2017 | 344 | 0.930 |
Why?
|
| Treatment Outcome | 34 | 2025 | 5834 | 0.860 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2018 | 316 | 0.780 |
Why?
|
| Aged, 80 and over | 30 | 2020 | 5682 | 0.750 |
Why?
|
| Lymphoma | 3 | 2019 | 101 | 0.690 |
Why?
|
| Receptors, Notch | 2 | 2012 | 110 | 0.690 |
Why?
|
| Clinical Trials as Topic | 5 | 2017 | 462 | 0.680 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2013 | 128 | 0.660 |
Why?
|
| Taxoids | 5 | 2017 | 25 | 0.660 |
Why?
|
| Benzimidazoles | 2 | 2019 | 55 | 0.650 |
Why?
|
| Albumins | 2 | 2017 | 46 | 0.640 |
Why?
|
| Precision Medicine | 3 | 2017 | 134 | 0.640 |
Why?
|
| Paclitaxel | 2 | 2017 | 102 | 0.630 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 223 | 0.630 |
Why?
|
| Drugs, Investigational | 2 | 2017 | 12 | 0.610 |
Why?
|
| Benzamides | 2 | 2019 | 69 | 0.610 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 859 | 0.600 |
Why?
|
| Anilides | 4 | 2013 | 18 | 0.600 |
Why?
|
| Pyridines | 5 | 2014 | 120 | 0.580 |
Why?
|
| Piperidines | 1 | 2019 | 73 | 0.580 |
Why?
|
| ras Proteins | 4 | 2014 | 76 | 0.540 |
Why?
|
| Immunotherapy | 4 | 2025 | 274 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 588 | 0.540 |
Why?
|
| Camptothecin | 3 | 2017 | 29 | 0.540 |
Why?
|
| Gastrostomy | 1 | 2017 | 30 | 0.520 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2025 | 273 | 0.520 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.520 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 11 | 0.520 |
Why?
|
| Enteral Nutrition | 1 | 2017 | 53 | 0.520 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 297 | 0.520 |
Why?
|
| Nutritional Status | 1 | 2017 | 101 | 0.510 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 11 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2011 | 264 | 0.500 |
Why?
|
| Drug Interactions | 1 | 2017 | 126 | 0.500 |
Why?
|
| Transcriptome | 3 | 2017 | 408 | 0.490 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 182 | 0.490 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 94 | 0.480 |
Why?
|
| Prognosis | 11 | 2020 | 1793 | 0.480 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2013 | 15 | 0.480 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 286 | 0.470 |
Why?
|
| Drug Repositioning | 1 | 2016 | 11 | 0.470 |
Why?
|
| Carcinoma, Large Cell | 3 | 2011 | 5 | 0.460 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 35 | 0.460 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 233 | 0.450 |
Why?
|
| Mesothelioma | 2 | 2012 | 28 | 0.430 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 323 | 0.430 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 404 | 0.430 |
Why?
|
| Drug Administration Schedule | 12 | 2020 | 296 | 0.420 |
Why?
|
| DNA Copy Number Variations | 4 | 2017 | 73 | 0.410 |
Why?
|
| Cost of Illness | 1 | 2015 | 169 | 0.410 |
Why?
|
| Genes, Neoplasm | 2 | 2012 | 25 | 0.400 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2013 | 8 | 0.390 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 124 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 875 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2020 | 65 | 0.380 |
Why?
|
| Cyclodextrins | 1 | 2013 | 15 | 0.380 |
Why?
|
| Pyrazoles | 3 | 2014 | 88 | 0.380 |
Why?
|
| Nanoparticles | 3 | 2016 | 553 | 0.380 |
Why?
|
| Survival Rate | 6 | 2020 | 849 | 0.380 |
Why?
|
| RNA, Messenger | 8 | 2018 | 1583 | 0.380 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2012 | 2 | 0.380 |
Why?
|
| Quinazolines | 2 | 2012 | 21 | 0.380 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 59 | 0.370 |
Why?
|
| Cellulose | 1 | 2013 | 46 | 0.370 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2017 | 52 | 0.370 |
Why?
|
| Disease Progression | 6 | 2017 | 1229 | 0.370 |
Why?
|
| Oncogenes | 3 | 2025 | 70 | 0.370 |
Why?
|
| Nasal Cavity | 1 | 2012 | 9 | 0.370 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2012 | 2 | 0.370 |
Why?
|
| Pyrimidines | 4 | 2017 | 144 | 0.370 |
Why?
|
| Patient Selection | 2 | 2012 | 484 | 0.360 |
Why?
|
| Nose Neoplasms | 1 | 2012 | 17 | 0.360 |
Why?
|
| Cell Line, Tumor | 8 | 2026 | 1573 | 0.360 |
Why?
|
| Receptor, trkA | 1 | 2011 | 3 | 0.360 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 9 | 0.350 |
Why?
|
| Pleural Neoplasms | 1 | 2012 | 19 | 0.350 |
Why?
|
| Genetic Variation | 2 | 2020 | 396 | 0.340 |
Why?
|
| Oligonucleotides | 1 | 2013 | 229 | 0.340 |
Why?
|
| Phosphoramide Mustards | 1 | 2011 | 1 | 0.340 |
Why?
|
| Nitroimidazoles | 1 | 2011 | 4 | 0.340 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 190 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 50 | 0.330 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 44 | 0.330 |
Why?
|
| Patient Readmission | 1 | 2015 | 452 | 0.330 |
Why?
|
| Disease-Free Survival | 5 | 2015 | 245 | 0.330 |
Why?
|
| Salvage Therapy | 2 | 2010 | 75 | 0.330 |
Why?
|
| Thymoma | 1 | 2010 | 14 | 0.320 |
Why?
|
| Thymus Neoplasms | 1 | 2010 | 24 | 0.320 |
Why?
|
| Pemetrexed | 4 | 2012 | 11 | 0.310 |
Why?
|
| Cell Movement | 2 | 2012 | 484 | 0.310 |
Why?
|
| Genome | 1 | 2012 | 286 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 603 | 0.300 |
Why?
|
| Survival Analysis | 3 | 2020 | 579 | 0.300 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 64 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2026 | 203 | 0.290 |
Why?
|
| Young Adult | 8 | 2015 | 4883 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 1663 | 0.280 |
Why?
|
| Diarrhea | 4 | 2017 | 75 | 0.280 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1336 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 223 | 0.260 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 23 | 0.250 |
Why?
|
| Gene Library | 3 | 2018 | 102 | 0.250 |
Why?
|
| Heparin | 1 | 2007 | 120 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 542 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 49 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6957 | 0.230 |
Why?
|
| Fatigue | 5 | 2019 | 114 | 0.230 |
Why?
|
| Molecular Docking Simulation | 1 | 2026 | 81 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 375 | 0.230 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 310 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 61 | 0.220 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2005 | 10 | 0.220 |
Why?
|
| Heart-Assist Devices | 1 | 2007 | 158 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2026 | 136 | 0.220 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 60 | 0.220 |
Why?
|
| Nevus | 1 | 2005 | 23 | 0.220 |
Why?
|
| Scalp | 1 | 2005 | 30 | 0.220 |
Why?
|
| Genome, Human | 3 | 2017 | 238 | 0.210 |
Why?
|
| Area Under Curve | 5 | 2021 | 149 | 0.210 |
Why?
|
| Psoriasis | 2 | 2002 | 59 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2013 | 102 | 0.210 |
Why?
|
| Noonan Syndrome | 1 | 2004 | 2 | 0.210 |
Why?
|
| Nausea | 4 | 2019 | 111 | 0.210 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 911 | 0.210 |
Why?
|
| Skin Abnormalities | 1 | 2004 | 8 | 0.210 |
Why?
|
| TWEAK Receptor | 4 | 2017 | 5 | 0.210 |
Why?
|
| Craniofacial Abnormalities | 1 | 2004 | 23 | 0.210 |
Why?
|
| Proteome | 1 | 2025 | 153 | 0.200 |
Why?
|
| Hair Removal | 2 | 2002 | 10 | 0.200 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 172 | 0.200 |
Why?
|
| Biopsy | 2 | 2017 | 463 | 0.200 |
Why?
|
| Genomics | 3 | 2017 | 387 | 0.200 |
Why?
|
| Metagenomics | 2 | 2020 | 29 | 0.200 |
Why?
|
| Laser Therapy | 2 | 2002 | 41 | 0.200 |
Why?
|
| Anticoagulants | 1 | 2007 | 529 | 0.190 |
Why?
|
| Candida | 1 | 2023 | 37 | 0.190 |
Why?
|
| Heart Defects, Congenital | 1 | 2004 | 101 | 0.190 |
Why?
|
| Bacteria | 3 | 2021 | 337 | 0.190 |
Why?
|
| Proteomics | 1 | 2025 | 299 | 0.190 |
Why?
|
| Merkel cell polyomavirus | 1 | 2022 | 5 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 3 | 2013 | 417 | 0.190 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 9 | 0.190 |
Why?
|
| Tumor Virus Infections | 1 | 2022 | 26 | 0.180 |
Why?
|
| Adolescent | 7 | 2017 | 6368 | 0.180 |
Why?
|
| Polyomavirus Infections | 1 | 2022 | 31 | 0.180 |
Why?
|
| Smoothened Receptor | 2 | 2012 | 27 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2017 | 1030 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1172 | 0.180 |
Why?
|
| Administration, Oral | 4 | 2017 | 371 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 216 | 0.180 |
Why?
|
| Animals | 9 | 2026 | 21493 | 0.170 |
Why?
|
| Intellectual Disability | 1 | 2004 | 177 | 0.170 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 85 | 0.170 |
Why?
|
| Cellulitis | 1 | 2001 | 16 | 0.170 |
Why?
|
| Research Design | 2 | 2016 | 589 | 0.170 |
Why?
|
| Prednisone | 1 | 2001 | 83 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2001 | 37 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2012 | 141 | 0.160 |
Why?
|
| Candida albicans | 1 | 2020 | 61 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 327 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 899 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 2500 | 0.160 |
Why?
|
| Cisplatin | 2 | 2011 | 145 | 0.160 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 1 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2001 | 82 | 0.150 |
Why?
|
| Hope | 1 | 2019 | 10 | 0.150 |
Why?
|
| Vomiting | 2 | 2017 | 139 | 0.150 |
Why?
|
| Skin | 2 | 2002 | 436 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 75 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 169 | 0.150 |
Why?
|
| Mice | 6 | 2026 | 11185 | 0.140 |
Why?
|
| Drug Industry | 1 | 2019 | 41 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 3779 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 170 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 514 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2019 | 70 | 0.140 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2018 | 6 | 0.140 |
Why?
|
| DNA, Complementary | 1 | 2018 | 165 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 68 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 198 | 0.130 |
Why?
|
| Vinblastine | 1 | 2017 | 15 | 0.130 |
Why?
|
| Platinum | 1 | 2017 | 20 | 0.130 |
Why?
|
| Sulfoxides | 1 | 2017 | 16 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2017 | 17 | 0.130 |
Why?
|
| Emotions | 1 | 2019 | 236 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 289 | 0.130 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 20 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 993 | 0.130 |
Why?
|
| Sarcoma | 1 | 2017 | 36 | 0.130 |
Why?
|
| Exome | 1 | 2017 | 69 | 0.130 |
Why?
|
| Neutropenia | 1 | 2017 | 68 | 0.130 |
Why?
|
| Spasm | 2 | 2013 | 10 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 98 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2019 | 131 | 0.120 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 41 | 0.120 |
Why?
|
| Models, Biological | 3 | 2013 | 1193 | 0.120 |
Why?
|
| Organophosphorus Compounds | 1 | 2016 | 33 | 0.120 |
Why?
|
| Imidazoles | 2 | 2011 | 82 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2012 | 426 | 0.120 |
Why?
|
| Sequence Alignment | 1 | 2017 | 302 | 0.120 |
Why?
|
| Alopecia | 2 | 2013 | 31 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2014 | 20 | 0.120 |
Why?
|
| Drug Carriers | 2 | 2016 | 190 | 0.120 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 7 | 0.120 |
Why?
|
| Electrocardiography | 1 | 2019 | 556 | 0.120 |
Why?
|
| Base Sequence | 3 | 2014 | 1332 | 0.120 |
Why?
|
| Cyclopentanes | 1 | 2015 | 9 | 0.120 |
Why?
|
| Chondroitin Sulfates | 1 | 2015 | 11 | 0.120 |
Why?
|
| Imidazolines | 1 | 2015 | 1 | 0.110 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2015 | 11 | 0.110 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 8 | 0.110 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 43 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 33 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2015 | 34 | 0.110 |
Why?
|
| Pyrroles | 1 | 2015 | 50 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 32 | 0.110 |
Why?
|
| Antigens, Protozoan | 1 | 2015 | 67 | 0.110 |
Why?
|
| Placenta | 1 | 2015 | 73 | 0.110 |
Why?
|
| Anemia | 2 | 2014 | 132 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 420 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2021 | 3340 | 0.110 |
Why?
|
| Lung | 2 | 2011 | 969 | 0.110 |
Why?
|
| Prodrugs | 2 | 2014 | 36 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 7 | 0.100 |
Why?
|
| Receptors, LHRH | 1 | 2014 | 8 | 0.100 |
Why?
|
| Benzazepines | 1 | 2014 | 21 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 234 | 0.100 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 24 | 0.100 |
Why?
|
| Dysgeusia | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 214 | 0.100 |
Why?
|
| DNA Repair | 2 | 2012 | 263 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 63 | 0.100 |
Why?
|
| Cullin Proteins | 1 | 2013 | 10 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 746 | 0.100 |
Why?
|
| F-Box Proteins | 1 | 2013 | 16 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 220 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 74 | 0.100 |
Why?
|
| Veratrum Alkaloids | 1 | 2013 | 10 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 710 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1719 | 0.100 |
Why?
|
| Diphenylamine | 1 | 2013 | 4 | 0.100 |
Why?
|
| GTPase-Activating Proteins | 1 | 2013 | 69 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 27 | 0.100 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 46 | 0.090 |
Why?
|
| Hydroxylamines | 1 | 2012 | 7 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2022 | 1044 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 21 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 741 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1148 | 0.090 |
Why?
|
| Glypicans | 2 | 2022 | 6 | 0.090 |
Why?
|
| Demography | 1 | 2013 | 178 | 0.090 |
Why?
|
| Proteolysis | 1 | 2013 | 155 | 0.090 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2012 | 10 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2012 | 66 | 0.090 |
Why?
|
| Quality of Life | 1 | 2000 | 1266 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 504 | 0.090 |
Why?
|
| DNA | 1 | 2017 | 853 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 211 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 32 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 35 | 0.090 |
Why?
|
| Comorbidity | 2 | 2018 | 1122 | 0.090 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 21 | 0.090 |
Why?
|
| Retinal Dehydrogenase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Zinc Finger Protein Gli2 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 196 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2013 | 135 | 0.090 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2011 | 48 | 0.090 |
Why?
|
| Thioredoxins | 1 | 2011 | 17 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 70 | 0.090 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 2 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 56 | 0.080 |
Why?
|
| Protein Kinase C-alpha | 1 | 2011 | 17 | 0.080 |
Why?
|
| Disulfides | 1 | 2011 | 67 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2012 | 154 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 42 | 0.080 |
Why?
|
| cdc25 Phosphatases | 1 | 2011 | 7 | 0.080 |
Why?
|
| Small Molecule Libraries | 1 | 2011 | 57 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 290 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2011 | 100 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2011 | 218 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 36 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2010 | 16 | 0.080 |
Why?
|
| Ligands | 1 | 2011 | 414 | 0.080 |
Why?
|
| Antifungal Agents | 2 | 2002 | 125 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 205 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 78 | 0.080 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2010 | 1 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 196 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 611 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 518 | 0.070 |
Why?
|
| Thymus Gland | 1 | 2010 | 241 | 0.070 |
Why?
|
| RNA Interference | 1 | 2013 | 647 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2011 | 1561 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2020 | 2651 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1980 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 44 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2011 | 419 | 0.070 |
Why?
|
| RNA Polymerase II | 1 | 2008 | 86 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 811 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1235 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2023 | 89 | 0.070 |
Why?
|
| Sulindac | 1 | 2007 | 5 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 993 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2008 | 267 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 88 | 0.070 |
Why?
|
| Remission Induction | 1 | 2007 | 149 | 0.060 |
Why?
|
| Child | 2 | 2009 | 4653 | 0.060 |
Why?
|
| Algorithms | 1 | 2012 | 1060 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 793 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 378 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2007 | 10 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 32 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2007 | 61 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 20 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 37 | 0.060 |
Why?
|
| Computational Biology | 1 | 2008 | 369 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2007 | 180 | 0.060 |
Why?
|
| Oligopeptides | 2 | 2017 | 135 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2015 | 77 | 0.060 |
Why?
|
| Thrombosis | 1 | 2007 | 207 | 0.060 |
Why?
|
| Biological Availability | 2 | 2015 | 210 | 0.050 |
Why?
|
| Syndrome | 1 | 2004 | 182 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2004 | 54 | 0.050 |
Why?
|
| Half-Life | 2 | 2014 | 81 | 0.050 |
Why?
|
| Candidiasis | 1 | 2023 | 49 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 75 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 617 | 0.050 |
Why?
|
| Onychomycosis | 1 | 2002 | 6 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2002 | 17 | 0.050 |
Why?
|
| Dicarboxylic Acids | 1 | 2002 | 2 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1595 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2023 | 75 | 0.040 |
Why?
|
| Heterografts | 1 | 2022 | 67 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2022 | 24 | 0.040 |
Why?
|
| Acne Vulgaris | 1 | 2002 | 24 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2002 | 24 | 0.040 |
Why?
|
| Job Syndrome | 1 | 2001 | 2 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 1569 | 0.040 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2021 | 22 | 0.040 |
Why?
|
| Lichen Planus | 1 | 2001 | 9 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 709 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 134 | 0.040 |
Why?
|
| Lip Neoplasms | 1 | 2001 | 4 | 0.040 |
Why?
|
| Prevotella | 1 | 2021 | 2 | 0.040 |
Why?
|
| Herpes Zoster | 1 | 2001 | 22 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 193 | 0.040 |
Why?
|
| Lip | 1 | 2001 | 12 | 0.040 |
Why?
|
| Fungi | 1 | 2021 | 57 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 518 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 132 | 0.040 |
Why?
|
| Cachexia | 1 | 2021 | 13 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 64 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2022 | 149 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 314 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 712 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 195 | 0.040 |
Why?
|
| Bacteroidetes | 1 | 2020 | 6 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 105 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2001 | 72 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 248 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 183 | 0.040 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2000 | 6 | 0.040 |
Why?
|
| Scalp Dermatoses | 1 | 2000 | 5 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 856 | 0.040 |
Why?
|
| Spinal Cord Compression | 1 | 2000 | 30 | 0.040 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2011 | 31 | 0.040 |
Why?
|
| Urea | 1 | 2000 | 42 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 377 | 0.040 |
Why?
|
| Exercise Test | 1 | 2021 | 257 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2001 | 117 | 0.040 |
Why?
|
| Lasers | 1 | 2000 | 39 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2001 | 202 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2329 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 84 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 122 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 231 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2000 | 606 | 0.040 |
Why?
|
| Stroke | 1 | 2007 | 1225 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2000 | 294 | 0.030 |
Why?
|
| Cell Line | 1 | 2022 | 2031 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1012 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 23 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 295 | 0.030 |
Why?
|
| Pain | 1 | 2000 | 400 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 32 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 2116 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2017 | 59 | 0.030 |
Why?
|
| Anxiety | 1 | 2000 | 427 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 281 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 442 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1294 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 4 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2739 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 35 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 8 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mohs Surgery | 2 | 2010 | 54 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 46 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2015 | 20 | 0.030 |
Why?
|
| Tendons | 1 | 2015 | 27 | 0.030 |
Why?
|
| Fasting | 1 | 2015 | 52 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 199 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 201 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 19 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 96 | 0.030 |
Why?
|
| Glycine | 1 | 2014 | 48 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 70 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 415 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 69 | 0.030 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 49 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 104 | 0.020 |
Why?
|
| DNA Primers | 1 | 2014 | 302 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 48 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 211 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 35 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 87 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 46 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2012 | 15 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2013 | 124 | 0.020 |
Why?
|
| Pregnancy | 2 | 2015 | 2401 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 127 | 0.020 |
Why?
|
| Muscle Neoplasms | 1 | 2012 | 9 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2012 | 20 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3506 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2012 | 19 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2013 | 292 | 0.020 |
Why?
|
| Liposomes | 1 | 2012 | 118 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 72 | 0.020 |
Why?
|
| Excipients | 1 | 2012 | 50 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 94 | 0.020 |
Why?
|
| Genes, ras | 1 | 2012 | 28 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 80 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 167 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 700 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 588 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 74 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 436 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 113 | 0.020 |
Why?
|
| Risk Factors | 1 | 2002 | 5475 | 0.020 |
Why?
|
| Nitriles | 1 | 2012 | 82 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 206 | 0.020 |
Why?
|
| Hyponatremia | 1 | 2011 | 11 | 0.020 |
Why?
|
| G2 Phase | 1 | 2011 | 23 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2011 | 15 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 1236 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2011 | 99 | 0.020 |
Why?
|
| Low-Level Light Therapy | 1 | 2010 | 12 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2009 | 10 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2009 | 13 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 963 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 926 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 965 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 2005 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 432 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1226 | 0.020 |
Why?
|
| Laparotomy | 1 | 2007 | 56 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2007 | 84 | 0.010 |
Why?
|
| Hypoglycemia | 1 | 2007 | 64 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 208 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 737 | 0.010 |
Why?
|
| United States | 1 | 2019 | 8189 | 0.010 |
Why?
|
| Glucose | 1 | 2007 | 478 | 0.010 |
Why?
|
| Emollients | 1 | 2002 | 4 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 51 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 1672 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 498 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 133 | 0.010 |
Why?
|
| Ointments | 1 | 2000 | 7 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 122 | 0.010 |
Why?
|